On May 21, Ascentage Pharma-B (06855.HK) rose 7.32% in regular trading, trading at HK$41.7/share, with trading volume of HK$55.33 million.

On the news front, the company held its annual general meeting on May 20, where management released multiple positive signals driving the rebound. Key highlights include: the core product APG-2575 (Lisaftoclax) will pursue independent commercialization rather than being out-licensed, with the company actively recruiting a US Chief Commercial Officer; management confirmed that collaboration with Takeda remains on track; and MDS (myelodysplastic syndromes) was designated as the highest-priority clinical program, with plans to file for fast-track designation in the second half of next year.

Additionally, the company's Bcl-2 inhibitor Lisaftoclax was recently included in two CSCO clinical practice guidelines, receiving authoritative recommendations in CLL/SLL, AML, and MDS indications. The convergence of these catalysts drove the stock to recover from a 5.19% decline earlier in the week when the broader innovative pharma sector experienced broad-based selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)